ArticleRadiology. Imaging cancer2026
Risk Model for Predicting Aggressive Recurrence of Hepatocellular Carcinoma after Microwave Ablation Using MRI and Clinical Parameters.
Article in Radiology. Imaging cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose To develop and validate a risk score model for predicting aggressive recurrence (AR) of hepatocellular carcinoma (HCC) after microwave ablation (MWA). Materials and Methods This retrospective study included consecutive patients with solitary HCC (≤3 cm) who underwent preoperative contrast-enhanced MRI and MWA from June 2014 to October 2019. In the training set, multivariable Cox regression analysis identified clinical, laboratory, and MWA parameters and MRI features associated with AR. The resulting predictive model, named Aggressive Recurrence after Microwave Ablation (ARMA), was evaluated in the test set using the concordance index (C-index) and compared with the Barcelona Clinic Liver Cancer staging system and known risk factors. Kaplan-Meier survival curves were compared using the log-rank test. Results A total of 393 eligible patients (mean age, 57.7 years ± 11.2 [SD]; 299 [76.1%] male) were included. AR occurred in 79 of 275 (28.7%) patients in the training set and 37 of 118 (31.4%) patients in the test set. Independent predictors of AR-free survival (ARFS) were periportal location (hazard ratio [HR], 1.72;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.